Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term Prognosis of Children With Bronchiectasis Treated With Low-dose Erythromycin Intervention
NCT03966066
Chronic Bronchiolitis or Resistant Asthma?
NCT00368342
ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene Expression
NCT06869382
Efficacy Study of Azithromycin-based Therapy for Bronchiolitis Obliterans
NCT01327625
Change of Airway Hyperresponsiveness to Mannitol and Methacholine in Patients With Asthma
NCT01725360
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Erythromycin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical, spirometric and radiological findings were compatible with BO on High Resolution Computed Tomography (HRCT)
* Non-responsiveness to high dose bronchodilator therapy
Exclusion Criteria
* History of cigarette smoking and occupational exposure to toxic agents of hypersensitivity to macrolides
* History of treatment with a systemic antibiotic within 7 days before the start of the study
* Any investigational medicine within 4 weeks of the study
* History of antibiotic injection within 6 weeks before the study
* Concomitant Theophylline or Carbamazepine, unless their serum concentrations were regularly monitored
* Patients who were in the exacerbation phase of their respiratory complications
* Need to use medications interact with macrolides such as Digoxin, Theophylline and Carbamazepine
* Systemic antibiotics
* Systemic Corticosteroids
* Admission to the hospital
* Abnormal kidney or liver function
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Baqiyatallah Medical Sciences University
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mostafa Ghanei, Professor
Role: STUDY_DIRECTOR
Research Center of Chemical Injuries, Baqyatallah Medical Sciences University, Tehran, Iran
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Baqiyatallah Medical Sciences University
Tehran, Tehran Province, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S-340-14-6-1-PU-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.